
Is Vitamin D Deficiency Linked to Insomnia?
Vitamin D is a fat-soluble vitamin that's important for your overall health. This nutrient is involved in maintaining the health of your bones, muscles, and immune system.
Despite its importance, many people don't have enough vitamin D. A 2022 study estimated that 22% of people in the United States have a moderate deficiency in vitamin D while 2.6% have a severe deficiency.
A vitamin D deficiency can have several notable effects on your health. One of these is insomnia.
What's the link between vitamin D and insomnia?
Insomnia is a sleep disorder where you have difficulty falling asleep or staying asleep. It's also associated with poor quality sleep, meaning you feel unrested and sleepy during the day, even if you do manage to get some sleep.
Researchers have observed an association between vitamin D deficiency and sleep disorders.
For example, a 2018 review of nine studies linked vitamin D deficiency to a higher risk of sleep disorders. It also associated vitamin D deficiency with poor sleep quality, shorter sleep duration, and increased sleepiness during the day.
How exactly vitamin D deficiency contributes to insomnia isn't known.
A 2020 review notes that receptors for vitamin D are found in areas of the brain associated with sleep. Although more research is needed, it seems that low levels of vitamin D impact how the body regulates sleep.
For example, vitamin D is involved in pathways used to make melatonin, a hormone important for the sleep-wake cycle. It may also help regulate genes that code for other proteins that are involved in controlling sleep.
What are the symptoms of low vitamin D?
Most people with vitamin D deficiency are asymptomatic, which means they don't have any noticeable symptoms.
When symptoms are present, they may include things like:
fatigue
muscle pain
muscle weakness
bone and joint pain
mood changes, such as feeling depressed
Long-term vitamin D deficiency can have negative effects on bone health, leading to rickets in children and osteomalacia in teens and adults.
Can taking vitamin D help insomnia?
If you've been experiencing insomnia lately, you may be wondering if taking a vitamin D supplement will help you get a better night's sleep. Overall, the research into this is mixed.
A 2018 clinical trial involving 89 participants with sleep disorders found that taking a 50,000 IU supplement every 2 weeks for 8 weeks improved sleep quality, reduced the time it took to fall asleep, and boosted sleep duration.
However, a 2021 clinical trial involving 189 participants with vitamin D deficiency found that taking a 20,000 IU supplement of vitamin D weekly for 4 months showed no improvement in sleep duration, daytime sleepiness, or insomnia.
A 2022 review of studies reported that vitamin D supplementation may boost sleep quality. However, the authors noted that this finding should be interpreted with caution due to the limited research into this topic.
They also mention that they couldn't find enough data looking at the effects of vitamin D supplements on specific sleep disorders.
»MORE: Vitamin D benefits.
Can taking vitamin D cause insomnia?
It may seem counterintuitive, but taking too much vitamin D may also lead to sleep troubles. This goes back to the link between vitamin D and melatonin.
Melatonin is a hormone that promotes sleep and its production increases as it gets dark out. Meanwhile, vitamin D can be made during exposure to sunlight.
A 2023 review notes that there's a negative correlation between the two. This means that as vitamin D increases, melatonin may decrease.
In fact, an older study involving 40 people with multiple sclerosis (MS) found just this. Daily supplementation with a high dose (4,370 IU) of vitamin D decreased nighttime levels of melatonin. Meanwhile, a lower daily dose (800 IU) did not affect melatonin levels.
So it's possible that taking too much vitamin D may lead to trouble sleeping.
That's why it's important to chat with a healthcare professional before starting a new supplement. They can recommend how much to take and also make you aware of any potential side effects.
»MORE: Vitamin D dosage.
Takeaway
Researchers have linked vitamin D deficiency to an increased risk of sleep disorders like insomnia. The exact reason for this isn't known, but it appears to be linked to vitamin D's role in pathways associated with sleep.
While it's possible that vitamin D supplementation may improve sleep quality, research into this topic has been mixed. Additionally, taking too much vitamin D may have the opposite effect and actually interfere with sleep.
If you're worried that a vitamin D deficiency may be contributing to your sleep troubles, visit a healthcare professional to discuss your concerns. A simple blood test can be used to confirm or rule out a deficiency.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
UnitedHealth's $3.3bn Amedisys deal faces strict divestiture terms
The US Justice Department's Antitrust Division has reached a settlement with health insurer UnitedHealth Group over its $3.3bn acquisition of Amedisys. UnitedHealth, which previously acquired LHC Group, a competitor to Amedisys, faced legal challenges last year when the Justice Department and state attorneys general moved to block the acquisition. Amedisys provides home health and hospice services, and is based in Baton Rouge, Louisiana. The proposed settlement stipulates that UnitedHealth must relinquish ownership of 164 home health and hospice facilities, including one palliative care centre, spread across 19 US states. These facilities collectively generate annual revenue of around $528m. Additionally, the settlement imposes a contingency that requires UnitedHealth to divest eight more locations should it encounter regulatory hurdles in the initial divestiture process. To ensure adherence to the terms, a monitoring body will be appointed to oversee the divestiture and the execution of the consent decree. The buyers of the divested assets should be equipped with the necessary resources, staff and business relationships to foster competition in areas where UnitedHealth previously had a presence. Amedisys has also been directed to pay a civil penalty of $1.1m for inaccurately certifying compliance with the Hart-Scott-Rodino Antitrust Improvements Act. The company is further mandated to conduct antitrust compliance training for its leadership to prevent future misrepresentations in its communications with the US Government. The Justice Department's Antitrust Division Assistant Attorney General, Abigail Slater, said: 'In no sector of our economy is competition more important to Americans' well-being than healthcare. This settlement protects quality and price competition for hundreds of thousands of vulnerable patients and wage competition for thousands of nurses.' Earlier this month, UnitedHealth named Wayne DeVeydt as its new CFO, replacing John Rex, who will transition to a strategic advisory role. "UnitedHealth's $3.3bn Amedisys deal faces strict divestiture terms " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
25 minutes ago
- Yahoo
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the 'Company' or 'ProPhase'), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company's investor website. REGISTER HERE: To ensure smooth connectivity, please access this link using the latest version of Google Chrome. About ProPhase Labs Inc. ProPhase Labs Inc. (Nasdaq: PRPH) ('ProPhase') is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. Media Relations and Institutional Investor Contact:ProPhase Labs, Retail Investor Relations Contact:Renmark Financial Communications Boidman: jboidman@ (416) 644-2020 or (212) in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Baron Small Cap Fund is Excited to Invest in Hinge Health (HNGE). Here's Why
Baron Funds, an investment management company, released its 'Baron Small Cap Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, the fund was up 10.38%% (Institutional Shares) compared to the Russell 2000 Growth Index's (the Index) 11.97% return. Year to date, the Fund is up 0.36% compared to the index's (0.48)% return. Small-cap stocks recovered well during the quarter and performed in line with the overall market but have significantly trailed larger-cap stocks this year. In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Small Cap Fund highlighted stocks such as Hinge Health, Inc. (NYSE:HNGE). Hinge Health, Inc. (NYSE:HNGE) is a health care software developer for joint and muscle health. The one-month return of Hinge Health, Inc. (NYSE:HNGE) was 18.26%. On August 8, 2025, Hinge Health, Inc. (NYSE:HNGE) stock closed at $56.68 per share, with a market capitalization of $4.422 billion. Baron Small Cap Fund stated the following regarding Hinge Health, Inc. (NYSE:HNGE) in its second quarter 2025 investor letter: "We established a position at Hinge Health, Inc. (NYSE:HNGE) on its May IPO. Hinge Health is a digital health care provider delivering virtual physical therapy, leveraging AI empowered software and hardware designed to deliver a broad spectrum of musculoskeletal (MSK) care. Four times larger than its next competitor, Hinge Health's highly scalable platform facilitates personalized and largely automated MSK care through AI powered motion tracking (TrueMotion) and an FDA approved proprietary nerve simulation wearable device (Enso) supported by a care team of licensed Physical Therapists, MDs, and board-certified coaches. A female doctor using the latest healthcare IT technology in her medical practice. Hinge Health, Inc. (NYSE:HNGE) is not on our list of 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the potential of Hinge Health, Inc. (NYSE:HNGE) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Hinge Health, Inc. (NYSE:HNGE) and shared the list of stocks Jim Cramer discussed recently. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data